Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Telix Pharmaceuticals (TLX) Current Deferred Revenue (2023 - 2025)

Telix Pharmaceuticals (TLX) posted Current Deferred Revenue of $402000.0 for Q4 2025, down 94.53% on a QoQ basis from $7.4 million in Q4 2024, and down 94.53% year-over-year from $7.4 million in Q4 2024.

Telix Pharmaceuticals (TLX) has 3 years of Current Deferred Revenue data on file, last reported at $402000.0 in Q4 2025.

  • In Q4 2025, Current Deferred Revenue fell 94.53% year-over-year to $402000.0; the TTM figure through Dec 2025 stood at $402000.0 (down 94.53% YoY), while the FY2025 annual figure was $402000.0, down 94.23% from the prior year.
  • Current Deferred Revenue retreated to $402000.0 in Q4 2025, from $7.4 million in the prior quarter.
  • Across five years, Current Deferred Revenue topped out at $7.4 million in Q4 2024 and bottomed at $402000.0 in Q4 2025.
  • A 3-year average of $5.0 million and a median of $7.2 million in 2023 frame the typical range for Current Deferred Revenue.
  • Annual changes were most pronounced in 2024 — Current Deferred Revenue rose 2.77% — and 2025, when it sank 94.53%.
  • Year by year, Current Deferred Revenue stood at $7.2 million in 2023, then grew by 2.77% to $7.4 million in 2024, then sank by 94.53% to $402000.0 in 2025.
  • The last three Current Deferred Revenue figures came in at $402000.0 (Q4 2025), $7.4 million (Q4 2024), and $7.2 million (Q4 2023), per Business Quant data.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Quantum Biopharma 961,148.99 Bn 961,148.98 Bn -
2 Alterity Therapeutics 744,933.29 Bn 744,933.26 Bn -
3 Legend Biotech 2,540.00 Bn 2,539.71 Bn 242.10 Mn
4 Nanobiotix 2,199.85 Bn 2,199.78 Bn -
5 Akari Therapeutics 1,635.88 Bn 1,635.88 Bn -
6 Vertex Pharmaceuticals 111.32 Bn 104.07 Bn 2.59 Bn
7 Evaxion A 62.56 Bn 62.54 Bn -
8 Regeneron Pharmaceuticals 62.55 Bn 53.79 Bn 3.31 Bn
9 Alnylam Pharmaceuticals 39.57 Bn 36.56 Bn 959.66 Mn
10 Telix Pharmaceuticals 4.52 Bn 4.38 Bn -

Historic Data

Download Data 🔒
DateValue
Dec 31, 2025 402,000.00
Dec 31, 2024 7.36 Mn
Dec 31, 2023 7.16 Mn